Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Tidbits from the Disclosure Statement

Agreed and the most important outcome for shareholders will be dividends paid out from any future licenses on a regular (e.g. quarterly) basis. It matters not how the lost value is returned to shareholders, what matters if that it is delivered.

Share
New Message
Please login to post a reply